Drug Trial Radar · NCT06594523
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis
Last checked: Nov 19, 2026Latest source record: May 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Mar 2025
Primary completion
Dec 2030
Study completion Dec 2030
Sponsor
- Lead sponsor
- Sagimet Biosciences Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized, double-blind, placebo-controlled Phase 3 study to determine if denifanstat 50 mg or 25 mg is effective, as compared to placebo, in resolving MASH without the worsening of fibrosis and/or in fibrosis regression without the worsening of steatohepatitis.
Conditions
- MASH
- NASH
- Metabolic Dysfunction-associated Steatohepatitis
- Noncirrhotic Metabolic Dysfunction-associated Steatohepatitis
- Nonalcoholic Steatohepatitis
- Nonalcoholic Fatty Liver
Interventions
DenifanstatDrug
Tablet
PlaceboDrug
Matching Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dual Primary Efficacy Endpoint 1: Interim Analysis: MASH Resolution (denifanstat 50 mg compared to placebo)Time frame: 52 weeks
- Dual Primary Efficacy Endpoint 2: Interim Analysis: Improvement in Fibrosis (denifanstat 50 mg compared to placebo)Time frame: 52 weeks
- Primary Endpoint: End of Study Analysis: Liver-related Composite Clinical Outcome (denifanstat 50 mg compared to placebo)Time frame: 234 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.